APA (7th ed.) Citation

Carta, A., Del Zompo, M., Meloni, A., Mola, F., Paribello, P., Pinna, F., . . . Conversano, C. (2022). Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective. Clinical Drug Investigation, 42(9), 733. https://doi.org/10.1007/s40261-022-01182-2

Chicago Style (17th ed.) Citation

Carta, Andrea, et al. "Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective." Clinical Drug Investigation 42, no. 9 (2022): 733. https://doi.org/10.1007/s40261-022-01182-2.

MLA (9th ed.) Citation

Carta, Andrea, et al. "Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective." Clinical Drug Investigation, vol. 42, no. 9, 2022, p. 733, https://doi.org/10.1007/s40261-022-01182-2.